Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia

Developments in Ophthalmology

Volumn 46, Issue , 2010, Pages 73-83

  Battaglia Parodi, Maurizio ^a   Iacono, Pierluigi ^b   Bandello, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ARTICLE; COMPARATIVE STUDY; DEGENERATIVE MYOPIA; DRUG ANTAGONISM; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROGNOSIS; RETINA FOVEA; SUBRETINAL NEOVASCULARIZATION; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; FOVEA CENTRALIS; HUMANS; INJECTIONS, INTRAOCULAR; MYOPIA, DEGENERATIVE; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84925946032     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000320010     Document Type: Article

References (38)

1. Hotchkiss ML, Fine SL: Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 1981;91:177-183.
2. Curtin BJ: Basic science and clinical management; in Curtin BJ (ed): The Myopias. Philadelphia, Harper & Row, 1985, pp 237-245.
3. Tokoro T: Criteria for diagnosis of pathologic myopia; in Tokoro T (ed): Atlas of Posterior Fundus Changes in Pathologic Myopia. New York, Springer, 1998, pp 1-2.
4. Grossniklaus HE, Green WR: Pathologic findings in pathologic myopia. Retina 1992;12:127-133.
5. Avila M P, Weiter JJ, Jalkh AE, et al: Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581.
6. Grossniklaus HE, Gass J D M: Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998;126:59-69.
7. Takeshi Y, Kyoko OM, Kenjiro Y, et al: Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110:1297-1305.
8. Vongphanit J, Mitchell P, Wang JJ: Prevalence and progression of myopic retinopathy in an older population. Ophthalmology 2002;109:704-711.
9. Yoshida T, Ohno-Matsui K, Ohtake Y, et al: Longterm visual prognosis of choroidal neovascularization in high myopia. Ophthalmology 2002;109:712-719.
10. Yoshida T, Ohno-Matsui K, Yasazumi K, et al: Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110:1297-1305.
11. Bottoni F, Tilanus M: The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int Ophthalmol 2001;24:249-255.
12. Hayashi K, Ohno-Matsui K, Yoshida T, Kobayashi K, Kojima A, Shimada N, Yasuzumi K, Futagami S, Tokoro T, Mochizuki M: Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2005;243:13-19.
13. Brancato R, Menchini U, Pece A, et al: Dye laser photocoagulation of macular subretinal neovascularization in pathological myopia. A randomized study of three different wavelengths. Int Ophthalmol 1988;11:235-238.
14. Fardeau C, Soubrane G, Coscas G: Photocoagulation de néovaisseaux sous-rétinien compliquant la dégé-nérescence myopique. Bull Soc Ophtalmol Fr 1992;3:239-242.
15. Soubrane G, Pisan J, Bornert P, Perrenoud F, Coscas G: Néovaisseaux sous-retiniens de la myopie dégé- nérative: résultats de la photocoagulation. Bull Soc Ophtalmol Fr 1986;86:269-272.
16. Secretan M, Kuhn D, Soubrane G, et al: Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997;7:307-316.
17. Cohen SY, Bulik A, Dubois L, Quentel G: Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am J Ophthalmol 2003;136:371-374.
18. Lam DS, Liu DT, Fan DS, et al: Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia: one-year results of a prospective series. Eye 2005;19:834-840.
19. Verteporfin in Photodynamic Therapy (VIP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: one-year results of a randomized clinical trial - VIP report No. 1. Ophthalmology 2001;108:841-852.
20. Blinder KJ, Blumenkranz MS, Bressler NM, et al: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: two-year results of a randomized clinical trial - VIP report No. 3. Ophthalmology 2003;110:667-673.
21. Kobayashi H, Kobayashi K: Radiotherapy for subfoveal neovascularization associated with pathological myopia: a pilot study. Br J Ophthalmol 2000;84:761-766.
22. Ruiz-Moreno JM, de la Vega C: Surgical removal of subfoveal choroidal neovascularization in highly myopic patients. Br J Ophthalmol 2001;85:1041-1043.
23. Hamelin N, Glacet-Bernard A, Brindeau C, et al: Surgical treatment of subfoveal neovascularization in myopia: macular translocation versus surgical removal. Am J Ophthalmol 2002;133:530-536.
24. Ferrara N, Gerber H P, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
25. Sakaguchi H, Ikuno Y, Kamei M, et al: Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165.
26. Mandal S, Venkatesh P, Sampangi R, et al: Intravitreal bevacizumab (avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 2007;17:620-626.
27. Rensch F, Spandau UH, Schlichtenbrede F, et al: Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 2008;39:182-185.
28. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB: Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147:84-93.
29. Wu PC, Chen YJ: Intravitreal injection of bevacizumab for myopic choroidal neovascularization: one-year follow-up. Eye 2009;23:356-361.
30. Ikuno Y, Sayanagi K, Soga K, et al: Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
31. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S: Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: oneyear outcome. Br J Ophthalmol 2009;93:448-451.
32. Chan WM, Lai T Y, Chan KP, et al: Intravitreal bevacizumab (avastin) for myopic choroidal neovascularisation: one-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150.
33. Hayashi K, Ohno-Matsui K, Shimada N, et al: Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2009;247:609-618.
34. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al: Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye 2009;23:334-348.
35. Lai T Y, Chan WM, Liu DT, Lam DS: Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009;29:750-756.
36. Silva RM, Ruiz-Moreno JM, Nascimento J, et al: Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-1123.
37. Arias L, Planas L, Prades S, et al: Intravitreal bevacizumab (avastin) for choroidal neovascularisation secondary to pathologic myopia: six-month results. Br J Ophthalmol 2008;92:1035-1039.
38. Axer-Siegel L, Ehrlich R, Weimberger D, et al: Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 2004;138:602-607.